Health economics & outcomes research
Determining the value of a pharmaceutical product, diagnostic test, or medical device for candidate populations is essential in today’s competitive environment.
With clinical realism plus the seamless inclusion of claims, trial, health outcomes, patient quality of life, adherence/compliance, and pricing data, Archimedes solutions are ideally suited for comparative-effectiveness analyses, cost-effectiveness studies, and other health economics and outcomes research.
ARCHeS gives you the flexibility to experiment with multiple data sources, study inputs, and approaches, so user can position products to maximize market access, pricing, and competitive position.
Clinical trial simulations
Clinical researchers and medical affairs professionals are under pressure to develop trials that answer the right questions in a pre-specified time frame — within a reasonable budget.
ARCHeS allows users to explore the impact of changes to inclusion and exclusion criteria, protocol design variations, and the sensitivity of event rates for their patient group profile. These results can be combined in a single environment with data from previous proprietary and public trials, giving organizations new confidence in their predictive strategies.
CV safety trial planning
With new regulatory requirements requiring drugs to demonstrate adequate cardiovascular safety before, upon, and in some cases after approval, proper trial design and endpoint selection have never been more critical.
ARCHeS allows users to fine-tune their clinical trials with great speed and flexibility. By providing immediate insight into how patient comorbidity profiles or trial modifications will affect event rates, users can estimate sample size and develop trials that deliver results.
Understanding the impact of novel interventions with new therapeutics is an important part of any pharmaceutical development strategy. With Archimedes, researchers can easily and effectively predict the impact of new treatments on targeted patient populations, including biomarker response, long-term health outcomes, and costs.
Leading organizations are calculating the commercial value of new interventions earlier and earlier in the development cycle. This allows them to strategically position their assets, maximize value by optimizing Target Product Profiles, and enable early stage redirection or termination of non-valuable assets. When handled correctly, billions in development and opportunity costs can be saved.
ARCHeS supports these activities by providing an integrated analytics and modeling environment that simulates new scenarios, compares them to existing and trusted data sources, and optimizes your output.